1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Product Code | LNCaP-Clone-FGC; LNCaP.FGC; LNCaP-FGC; LNCaP FGC; LNCAPCLONEFGC |
| Species | Human |
| Cat.No | ABC-TC0599 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Prostate Cancer Cell Lines |
The LNCaP cell line was established in 1977 from a metastatic lesion in the left supraclavicular lymph node of a 50-year-old Caucasian male with prostate carcinoma. These cells grow in aggregates or as single cells, with a weak attachment to the substrate and a tendency to rapidly acidify the growth medium. LNCaP cells have a high affinity for androgen receptors and respond to hormonal stimulation. Unlike other cell lines, they do not form a uniform monolayer, instead growing in clusters that require dissociation for subculture. They are tumorigenic in immunodeficient mice and are frequently used for prostate cancer research. LNCaP cells are free from mycoplasma, bacteria, yeast, and fungi. These cells serve as an excellent in vitro model for studying prostate cancer, androgen receptor signaling, and drug resistance.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
The LNCaP cell line can be used to develop the CDX-type LNCaP mouse model. This model is valuable for studying androgen sensitivity, as LNCaP cells possess a mutated androgen receptor (AR T877A). The LNCaP xenograft model serves as an androgen-dependent system and is utilized for evaluating various treatment modalities targeting the androgen receptor, such as AR-targeting oligos or bicalutamide. This model provides a platform to study how well these treatments work and how they function in the context of androgen-dependent prostate cancer.
